Virtual Park for Children: Dual-Task Training with Virtual Reality

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study examines a two-phase approach for children and adolescents with neuromuscular disorders. Phase 1 provides standard therapy for three months, followed by Phase 2 where participants undergo a rehabilitative dual-task cycling program using a Virtual Park application three times weekly for three months. The trial aims to see if the Virtual Park intervention can slow functional motor decline and improve neuropsychological function and engagement compared with standard therapy alone. Eligible participants are aged 6 to 17 years, with a defined neuromuscular diagnosis, sufficient height to use the equipment, and a baseline upper limb function above threshold. The study is conducted across multiple Italian centers with a lead sponsor and collaborating institutes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* availability of a definitive clinical or molecular genetic diagnosis of a neuromuscular disease;
* age between 6 years and 17 years and 11 months (inclusive);
* height compatible with the use of the Thera-Trainer (minimum 120 cm);
* performance Upper Limb Module 2.0 assessment: Entry level \>= 2

Exclusion Criteria:

* other concomitant genetic diseases;
* presence of visual impairments that prevent access to the experimental virtual reality protocol;
* concomitant compromised cardio-respiratory function that contraindicates cycle ergometer training;
* severe osteoporosis.

Where it's running

• IRCCS E. Medea - La Nostra Famiglia
  Bosisio Parini, Lc, Italy Recruiting
• IRCCS Fondazione Stella Maris
  Pisa, Pi, Italy Recruiting
• IRCCS Fondazione Mondino
  Pavia, Pv, Italy Recruiting
• Fondazione Don Gnocchi - Centro "S. Maria al Mare"
  Salerno, Sa, Italy Suspended

Study contacts

• Study coordinator: Sara Arlati, Bioengineer
• Email: sara.arlati@cnr.it
• Phone: (+39)03412350202

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Duchenne/Becker Muscular Dystrophy EHR Data Linkage

  This study tests whether consented patients’ electronic health records can be linked with the Duchenne Registry data to create a richer view of Duchenne and Becker muscular dystrophy care.

  Recruiting at 11 sites The Duchenne Registry · Little Rock, Arkansas and 10 other locations · NCT07609394

• Zeleciment Rostudirsen (DYNE-251) for Duchenne Muscular Dystrophy in Ambulatory Boys

  This trial tests whether intravenous Zeleciment Rostudirsen (DYNE-251) given every 4 weeks is safe and helps improve function in ambulatory boys with Duchenne muscular dystrophy who have a specific dystrophin gene mutation.

  Recruiting Phase 3 Dyne Therapeutics · Hillsborough, North Carolina · NCT07608432

• AOC 1044 in Duchenne Muscular Dystrophy with Exon 44 Skipping

  This study tests whether intravenous AOC 1044 helps boys with Duchenne muscular dystrophy caused by mutations amenable to exon 44 skipping.

  Recruiting at 20 sites Phase 3 Avidity Biosciences, Inc. · Westmead, New South Wales and 19 other locations · NCT07587242

• Implanted brain interface to let people with severe paralysis control assistive devices

  It will try an implanted brain interface that records and stimulates brain signals so adults with severe paralysis can control assistive devices and receive sensory feedback.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07521930

• Measuring muscle health with a handheld electrical impedance device (mScan)

  This project will test whether a handheld mScan device can quickly measure muscle health in adults with myopathies and in people without muscle disease by comparing its readings to MRI.

  Recruiting Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07502989

• miR-1 as a blood biomarker for muscular dystrophies and congenital myopathies

  This project will see if levels of a blood molecule called miR-1 can track disease status in people with Duchenne/Becker muscular dystrophy, myotonic dystrophy type 1, congenital myopathies, and in healthy volunteers.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT07415837

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.